Search hospitals > Delaware > Newark

Helen F. Graham Cancer Center

Claim this profile
Newark, Delaware 19713
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
345 reported clinical trials
7 medical researchers
Photo of Helen F. Graham Cancer Center in NewarkPhoto of Helen F. Graham Cancer Center in NewarkPhoto of Helen F. Graham Cancer Center in Newark

Summary

Helen F. Graham Cancer Center is a medical facility located in Newark, Delaware. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Helen F. Graham Cancer Center is involved with conducting 345 clinical trials across 442 conditions. There are 7 research doctors associated with this hospital, such as Timothy D. Moore, Gregory A. Masters, Mark E. Borowsky, and Aine E. Clements.

Area of expertise

1Cancer
Global Leader
Helen F. Graham Cancer Center has run 131 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Helen F. Graham Cancer Center has run 57 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
ER positive

Top PIs

Clinical Trials running at Helen F. Graham Cancer Center

Breast Cancer
Lung Cancer
Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Squamous Cell Carcinoma
Diffuse Large B-Cell Lymphoma
Tumors
Oropharyngeal Carcinoma
Gastroesophageal Junction Adenocarcinoma
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This study is evaluating whether a drug used to treat high blood pressure and heart failure may help prevent heart damage in patients with breast cancer.
Recruiting2 awards Phase 323 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Helen F. Graham Cancer Center?
Helen F. Graham Cancer Center is a medical facility located in Newark, Delaware. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Helen F. Graham Cancer Center is involved with conducting 345 clinical trials across 442 conditions. There are 7 research doctors associated with this hospital, such as Timothy D. Moore, Gregory A. Masters, Mark E. Borowsky, and Aine E. Clements.
Where is Helen F. Graham Cancer Center located?
The Helen F. Graham Cancer Center & Research Institute is situated on the Christiana Hospital campus, located at 4701 Ogletown-Stanton Road, Newark, DE 19713. For directions, take I-95 to Exit 1B, follow DE-896 N towards Newark for about 2 miles, then turn left onto DE-4 E/Ogletown Stanton Rd. Continue for approximately 1 mile to find the hospital campus on your right.
Who should I call to ask about financial aid or insurance network?
For financial assistance at the Helen F. Graham Cancer Center: - Contact your Patient Access Coordinator (PAC) through your doctor's office or via the Find a Doctor page. - For insurance inquiries, call the Cancer Care Management Department at 302-623-4700. - Location: 4701 Ogletown-Stanton Road, Newark, DE 19713.
What insurance does Helen F. Graham Cancer Center accept?
The Helen F. Graham Cancer Center accepts a wide range of insurance plans, including but not limited to Aetna HMO/POS, Amerihealth HMO/Keystone, Humana Medicare Advantage, BCBS – DE/MD/Out of Area, Cigna HMO/PPO, Medicaid (DE only), and United Healthcare. Patients are advised to verify coverage and any required authorizations or referrals directly with their insurance provider.
What awards or recognition has Helen F. Graham Cancer Center received?
The Helen F. Graham Cancer Center & Research Institute, located in Newark, Delaware, is renowned for its comprehensive multidisciplinary cancer care, serving over 219,000 patients annually. As a National Cancer Institute selected Community Cancer Center, it offers advanced medical, surgical, and radiation procedures, alongside diagnostic services. The center collaborates with prestigious institutions such as The Wistar Institute, the University of Delaware, Nemours / A.I. du Pont Hospital for Children, Rice University / BioScience Research Collaborative, and the Delaware Biotechnology Institute for cutting-edge cancer research.